tiprankstipranks
Trending News
More News >
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
US Market

Legend Biotech (LEGN) Stock Forecast & Price Target

Compare
455 Followers
See the Price Targets and Ratings of:

LEGN Analyst Ratings

Strong Buy
17Ratings
Strong Buy
15 Buy
2 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Legend
Biotech
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

LEGN Stock 12 Month Forecast

Average Price Target

$80.14
▲(154.57%Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $80.14 with a high forecast of $95.00 and a low forecast of $55.00. The average price target represents a 154.57% change from the last price of $31.48.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"28":"$28","45":"$45","62":"$62","79":"$79","96":"$96"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":80.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$80.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[28,45,62,79,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.32,34.37230769230769,39.424615384615386,44.47692307692308,49.52923076923077,54.581538461538464,59.63384615384616,64.68615384615384,69.73846153846154,74.79076923076923,79.84307692307692,84.89538461538461,89.94769230769231,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.32,33.22923076923077,37.13846153846154,41.04769230769231,44.956923076923076,48.86615384615385,52.77538461538462,56.684615384615384,60.59384615384616,64.50307692307692,68.41230769230769,72.32153846153847,76.23076923076923,{"y":80.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.32,31.295384615384616,33.27076923076923,35.246153846153845,37.22153846153846,39.19692307692308,41.17230769230769,43.14769230769231,45.12307692307692,47.098461538461535,49.073846153846155,51.04923076923077,53.02461538461539,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.01,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.02,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.48,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.36,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.01,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$95.00Average Price Target$80.14Lowest Price Target$55.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on LEGN
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Hold
1.65%
Upside
Reiterated
06/06/25
Legend Biotech's stock score is supported by strong sales growth and strategic developments highlighted in the earnings call, despite ongoing profitability challenges. Technical indicators and valuation concerns temper the overall outlook, though a robust cash position and positive future guidance provide optimism.
Barclays Analyst forecast on LEGN
Gena WangBarclays
Barclays
$94
Buy
198.60%
Upside
Reiterated
06/03/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Replimune Group (NASDAQ: REPL) and Qiagen (NYSE: QGEN)
J.P. Morgan Analyst forecast on LEGN
Jessica FyeJ.P. Morgan
J.P. Morgan
Buy
Reiterated
06/02/25
Legend Biotech's Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity
RBC Capital Analyst forecast on LEGN
Leonid TimashevRBC Capital
RBC Capital
$78
Buy
147.78%
Upside
Reiterated
06/02/25
RBC Capital Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Scotiabank Analyst forecast on LEGN
George FarmerScotiabank
Scotiabank
$76
Buy
141.42%
Upside
Reiterated
06/02/25
Legend Biotech (LEGN) Gets a Buy from Scotiabank
BMO Capital Analyst forecast on LEGN
Kostas BiliourisBMO Capital
BMO Capital
$90
Buy
185.90%
Upside
Reiterated
06/02/25
Buy Rating for Legend Biotech Driven by Carvykti's Market Position and Efficacy
BTIG
$91
Buy
189.07%
Upside
Reiterated
05/23/25
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)
Piper Sandler Analyst forecast on LEGN
Edward TenthoffPiper Sandler
Piper Sandler
$78
Buy
147.78%
Upside
Reiterated
05/23/25
Piper Sandler Keeps Their Buy Rating on Legend Biotech (LEGN)
Truist Financial Analyst forecast on LEGN
Asthika GoonewardeneTruist Financial
Truist Financial
$88$71
Buy
125.54%
Upside
Reiterated
05/14/25
Legend Biotech Corp. (LEGN) PT Lowered to $71 at Truist SecuritiesTruist Securities analyst Asthika Goonewardene lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $71.00 (from $88.00) while maintaining a Buy rating.
H.C. Wainwright Analyst forecast on LEGN
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$75
Buy
138.25%
Upside
Reiterated
05/14/25
Legend Biotech's Strong Market Position and Growth Potential Drive Buy Rating
TD Cowen Analyst forecast on LEGN
Yaron WerberTD Cowen
TD Cowen
$62
Buy
96.95%
Upside
Reiterated
05/13/25
TD Cowen reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, We Like The Profile At These LevelsTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
William Blair Analyst forecast on LEGN
Sami CorwinWilliam Blair
William Blair
Hold
Reiterated
05/13/25
William Blair Reaffirms Their Hold Rating on Legend Biotech (LEGN)
Raymond James Analyst forecast on LEGN
Sean McCutcheonRaymond James
Raymond James
$86
Buy
173.19%
Upside
Reiterated
05/13/25
Raymond James reiterates Outperform Rating on Legend Biotech Corp. (LEGN)Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
Jefferies Analyst forecast on LEGN
Kelly ShiJefferies
Jefferies
$91
Buy
189.07%
Upside
Reiterated
05/13/25
Legend Biotech's Carvykti: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
Cantor Fitzgerald Analyst forecast on LEGN
Rick BienkowskiCantor Fitzgerald
Cantor Fitzgerald
$55
Buy
74.71%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Astria Therapeutics (NASDAQ: ATXS)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on LEGN
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Hold
1.65%
Upside
Reiterated
06/06/25
Legend Biotech's stock score is supported by strong sales growth and strategic developments highlighted in the earnings call, despite ongoing profitability challenges. Technical indicators and valuation concerns temper the overall outlook, though a robust cash position and positive future guidance provide optimism.
Barclays Analyst forecast on LEGN
Gena WangBarclays
Barclays
$94
Buy
198.60%
Upside
Reiterated
06/03/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Replimune Group (NASDAQ: REPL) and Qiagen (NYSE: QGEN)
J.P. Morgan Analyst forecast on LEGN
Jessica FyeJ.P. Morgan
J.P. Morgan
Buy
Reiterated
06/02/25
Legend Biotech's Carvykti Shows Strong Potential and Undervalued Stock Presents Attractive Investment Opportunity
RBC Capital Analyst forecast on LEGN
Leonid TimashevRBC Capital
RBC Capital
$78
Buy
147.78%
Upside
Reiterated
06/02/25
RBC Capital Reaffirms Their Buy Rating on Legend Biotech (LEGN)
Scotiabank Analyst forecast on LEGN
George FarmerScotiabank
Scotiabank
$76
Buy
141.42%
Upside
Reiterated
06/02/25
Legend Biotech (LEGN) Gets a Buy from Scotiabank
BMO Capital Analyst forecast on LEGN
Kostas BiliourisBMO Capital
BMO Capital
$90
Buy
185.90%
Upside
Reiterated
06/02/25
Buy Rating for Legend Biotech Driven by Carvykti's Market Position and Efficacy
BTIG
$91
Buy
189.07%
Upside
Reiterated
05/23/25
Analysts Are Bullish on These Healthcare Stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT)
Piper Sandler Analyst forecast on LEGN
Edward TenthoffPiper Sandler
Piper Sandler
$78
Buy
147.78%
Upside
Reiterated
05/23/25
Piper Sandler Keeps Their Buy Rating on Legend Biotech (LEGN)
Truist Financial Analyst forecast on LEGN
Asthika GoonewardeneTruist Financial
Truist Financial
$88$71
Buy
125.54%
Upside
Reiterated
05/14/25
Legend Biotech Corp. (LEGN) PT Lowered to $71 at Truist SecuritiesTruist Securities analyst Asthika Goonewardene lowered the price target on Legend Biotech Corp. (NASDAQ: LEGN) to $71.00 (from $88.00) while maintaining a Buy rating.
H.C. Wainwright Analyst forecast on LEGN
Mitchell KapoorH.C. Wainwright
H.C. Wainwright
$75
Buy
138.25%
Upside
Reiterated
05/14/25
Legend Biotech's Strong Market Position and Growth Potential Drive Buy Rating
TD Cowen Analyst forecast on LEGN
Yaron WerberTD Cowen
TD Cowen
$62
Buy
96.95%
Upside
Reiterated
05/13/25
TD Cowen reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, We Like The Profile At These LevelsTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
William Blair Analyst forecast on LEGN
Sami CorwinWilliam Blair
William Blair
Hold
Reiterated
05/13/25
William Blair Reaffirms Their Hold Rating on Legend Biotech (LEGN)
Raymond James Analyst forecast on LEGN
Sean McCutcheonRaymond James
Raymond James
$86
Buy
173.19%
Upside
Reiterated
05/13/25
Raymond James reiterates Outperform Rating on Legend Biotech Corp. (LEGN)Raymond James analyst Sean McCutcheon reiterated an Outperform rating and $86.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
Jefferies Analyst forecast on LEGN
Kelly ShiJefferies
Jefferies
$91
Buy
189.07%
Upside
Reiterated
05/13/25
Legend Biotech's Carvykti: Strong Growth Prospects and Strategic Expansion Justify Buy Rating
Cantor Fitzgerald Analyst forecast on LEGN
Rick BienkowskiCantor Fitzgerald
Cantor Fitzgerald
$55
Buy
74.71%
Upside
Reiterated
05/13/25
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN), Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) and Astria Therapeutics (NASDAQ: ATXS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Legend Biotech

1 Month
xxx
Success Rate
8/15 ratings generated profit
53%
Average Return
+0.97%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +0.97% per trade.
3 Months
xxx
Success Rate
6/15 ratings generated profit
40%
Average Return
-0.39%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -0.39% per trade.
1 Year
Edward TenthoffPiper Sandler
Success Rate
6/15 ratings generated profit
40%
Average Return
-10.77%
reiterated a buy rating 15 days ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -10.77% per trade.
2 Years
xxx
Success Rate
3/15 ratings generated profit
20%
Average Return
-18.57%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -18.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

LEGN Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
20
22
24
35
28
Buy
0
1
1
1
1
Hold
1
2
2
5
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
25
27
41
32
In the current month, LEGN has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. LEGN average Analyst price target in the past 3 months is 80.14.
Each month's total comprises the sum of three months' worth of ratings.

LEGN Financial Forecast

LEGN Earnings Forecast

Next quarter’s earnings estimate for LEGN is -$0.11 with a range of -$0.22 to $0.18. The previous quarter’s EPS was -$0.27. LEGN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.
Next quarter’s earnings estimate for LEGN is -$0.11 with a range of -$0.22 to $0.18. The previous quarter’s EPS was -$0.27. LEGN beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.

LEGN Sales Forecast

Next quarter’s sales forecast for LEGN is $232.39M with a range of $200.00M to $344.05M. The previous quarter’s sales results were $195.05M. LEGN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.
Next quarter’s sales forecast for LEGN is $232.39M with a range of $200.00M to $344.05M. The previous quarter’s sales results were $195.05M. LEGN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year LEGN has Outperformed its overall industry.

LEGN Stock Forecast FAQ

What is LEGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Legend Biotech Corporation’s 12-month average price target is 80.14.
    What is LEGN’s upside potential, based on the analysts’ average price target?
    Legend Biotech Corporation has 154.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is LEGN a Buy, Sell or Hold?
          Legend Biotech Corporation has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Legend Biotech Corporation’s price target?
            The average price target for Legend Biotech Corporation is 80.14. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $95.00 ,the lowest forecast is $55.00. The average price target represents 154.57% Increase from the current price of $31.48.
              What do analysts say about Legend Biotech Corporation?
              Legend Biotech Corporation’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of LEGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis